Mestinon (Pyridostigmine Bromide)

Pyridostigmine works by reversibly inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine. By slowing this breakdown, it increases the amount of acetylcholine available at neuromuscular junctions, thereby enhancing nerve‑to‑muscle signaling and improving muscle strength and gastrointestinal motility.

The appropriate dose of Mestinon is individualized by the prescribing clinician based on the patient’s condition, severity, age, renal function and response to therapy. Dosage adjustments are made during treatment to achieve optimal clinical benefit while minimizing side effects.

Safety data for pyridostigmine in pregnancy and lactation are limited. It should be used only when the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision. Women who are pregnant or nursing should discuss risks with their healthcare provider.

To order Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

The most common alternative is neostigmine, another acetylcholinesterase inhibitor. Pyridostigmine has a longer duration of action and is typically better tolerated for chronic use, whereas neostigmine is shorter‑acting and often used in acute settings such as postoperative reversal of neuromuscular blockade.

Mestinon should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Mestinon is taken orally, usually with a glass of water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable blood levels. Patients should follow the dosing schedule prescribed by their clinician.

Serious risks include cholinergic crisis, which can present as severe muscle weakness, respiratory failure, or paralysis; marked bradycardia or arrhythmias; severe bronchospasm; and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these symptoms occur.

Mestinon is contraindicated in individuals with known hypersensitivity to pyridostigmine or any excipients, in patients with mechanical intestinal obstruction, severe asthma or chronic obstructive pulmonary disease that could be worsened by increased bronchial secretions, and in those with uncontrolled cardiac arrhythmias.